K W Oppong1, M F Dawwas2, R M Charnley3, V Wadehra4, K Elamin2, S White3, M Nayar2. 1. HPB Unit, Freeman Hospital, Newcastle upon Tyne, UK; Department of Gastroenterology, Freeman Hospital, Newcastle upon Tyne, UK. Electronic address: Kofi.oppong@nuth.nhs.uk. 2. HPB Unit, Freeman Hospital, Newcastle upon Tyne, UK; Department of Gastroenterology, Freeman Hospital, Newcastle upon Tyne, UK. 3. HPB Unit, Freeman Hospital, Newcastle upon Tyne, UK; Department of Surgery, Freeman Hospital, Newcastle upon Tyne, UK. 4. Department of Cellular Pathology, Royal Victoria Infirmary, Newcastle upon Tyne, UK.
Abstract
BACKGROUND: Carcinoembryonic antigen (CEA) is suggested as the single most useful EUS/EUS-FNA derived test for the diagnosis of mucinous pancreatic cysts. STUDY AIMS: To investigate the yield and diagnostic performance of EUS/EUS-FNA on an intention to diagnose basis and to determine the utility of the recommended CEA and amylase cut-off values. PATIENTS AND METHODS: A retrospective study of a prospectively maintained database of 433 procedures performed in a 10 year period. Diagnostic performance of EUS-FNA was determined in 133 procedures with a definite diagnosis. RESULTS: CEA value was determined in significantly fewer procedures (58.6%) than EUS diagnosis was stated (83.4%; p < 0.0001), cyst fluid appearance recorded (89.4%) or adequate sample for cytology obtained (76.7%; p < 0.005). Median CEA was significantly higher in mucinous cysts than non-mucinous (175 ng/ml vs 3 ng/ml, p < 0.0001) and in malignant cysts compared to benign (8945 ng/ml vs 93 ng/ml, p < 0.001). On an intention-to-diagnose analysis, a CEA cut-off of 110 ng/ml was significantly less accurate (42.8%) than EUS diagnosis (67.7%), cytology (58.6%) or aspirate appearance (66.9%; p < 0.05 for all comparisons). However, the combination of EUS diagnosis, cytology and CEA provided higher sensitivity (91%), specificity (75%) and accuracy (85.7%) than each component test alone (p < 0.05 for all comparisons). Median amylase was significantly higher in benign compared to high-risk mucinous cysts ((11,429IU/L vs. 113IU/L; p < 0.05. CONCLUSION: The combination of EUS, cytology and CEA performed well. Malignant cysts had a higher CEA value than benign cysts. On an intention to diagnose basis a CEA cut-off of 110 ng/ml performed poorly.
BACKGROUND:Carcinoembryonic antigen (CEA) is suggested as the single most useful EUS/EUS-FNA derived test for the diagnosis of mucinous pancreatic cysts. STUDY AIMS: To investigate the yield and diagnostic performance of EUS/EUS-FNA on an intention to diagnose basis and to determine the utility of the recommended CEA and amylase cut-off values. PATIENTS AND METHODS: A retrospective study of a prospectively maintained database of 433 procedures performed in a 10 year period. Diagnostic performance of EUS-FNA was determined in 133 procedures with a definite diagnosis. RESULTS:CEA value was determined in significantly fewer procedures (58.6%) than EUS diagnosis was stated (83.4%; p < 0.0001), cyst fluid appearance recorded (89.4%) or adequate sample for cytology obtained (76.7%; p < 0.005). Median CEA was significantly higher in mucinous cysts than non-mucinous (175 ng/ml vs 3 ng/ml, p < 0.0001) and in malignant cysts compared to benign (8945 ng/ml vs 93 ng/ml, p < 0.001). On an intention-to-diagnose analysis, a CEA cut-off of 110 ng/ml was significantly less accurate (42.8%) than EUS diagnosis (67.7%), cytology (58.6%) or aspirate appearance (66.9%; p < 0.05 for all comparisons). However, the combination of EUS diagnosis, cytology and CEA provided higher sensitivity (91%), specificity (75%) and accuracy (85.7%) than each component test alone (p < 0.05 for all comparisons). Median amylase was significantly higher in benign compared to high-risk mucinous cysts ((11,429IU/L vs. 113IU/L; p < 0.05. CONCLUSION: The combination of EUS, cytology and CEA performed well. Malignant cysts had a higher CEA value than benign cysts. On an intention to diagnose basis a CEA cut-off of 110 ng/ml performed poorly.
Authors: Lawrence Mj Best; Vishal Rawji; Stephen P Pereira; Brian R Davidson; Kurinchi Selvan Gurusamy Journal: Cochrane Database Syst Rev Date: 2017-04-17
Authors: Yousuke Nakai; Takuji Iwashita; Susumu Shinoura; Do H Park; Jason B Samarasena; John G Lee; Kenneth J Chang Journal: Gastrointest Endosc Date: 2016-04-06 Impact factor: 9.427
Authors: Jose Lariño-Noia; Julio Iglesias-Garcia; Daniel de la Iglesia-Garcia; J Enrique Dominguez-Muñoz Journal: Endosc Ultrasound Date: 2018 Mar-Apr Impact factor: 5.628
Authors: Nan Ge; William R Brugge; Payal Saxena; Anand Sahai; Douglas G Adler; Marc Giovannini; Nonthalee Pausawasdi; Erwin Santo; Girish Mishra; William Tam; Mitsuhiro Kida; Jose G de la Mora-Levy; Malay Sharma; Muhammad Umar; Akio Katanuma; Linda Lee; Pramod Kumar Garg; Mohamad Ali Eloubeidi; Ho Khek Yu; Isaac Raijman; Brenda Lucia Arturo Arias; Manoop Bhutani; Silvia Carrara; Praveer Rai; Shuntaro Mukai; Laurent Palazzo; Christoph F Dietrich; Nam Q Nguyen; Mohamed El-Nady; Jan Werner Poley; Simone Guaraldi; Evangelos Kalaitzakis; Luis Carlos Sabbagh; Jose Lariño-Noia; Frank G Gress; Yuk-Tong Lee; Surinder S Rana; Pietro Fusaroli; Michael Hocke; Vinay Dhir; Sundeep Lakhtakia; Thawee Ratanachu-Ek; A S Chalapathi Rao; Peter Vilmann; Hussein Hassan Okasha; Atsushi Irisawa; Ryan Ponnudurai; Ang Tiing Leong; Everson Artifon; Julio Iglesias-Garcia; Adrian Saftoiu; Alberto Larghi; Carlos Robles-Medranda; Siyu Sun Journal: Endosc Ultrasound Date: 2019 Nov-Dec Impact factor: 5.628
Authors: Charlotte Vestrup Rift; Bojan Kovacevic; John Gásdal Karstensen; Julie Plougmann; Pia Klausen; Anders Toxværd; Evangelos Kalaitzakis; Carsten Palnæs Hansen; Jane Preuss Hasselby; Peter Vilmann Journal: World J Gastrointest Endosc Date: 2018-07-16